about
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trialImmune response against dying tumor cellsDendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha.Immunomodulatory effects of cyclophosphamide and implementations for vaccine design.Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemiaContribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy.From the antigen-presenting cell to the antigen-presenting vesicle: the exosomes.Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab.Exosomes for immunotherapy of cancer.Exosome-based immunotherapy.Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.The potential of exosomes in immunotherapy.The potential of exosomes in immunotherapy of cancer.Dendritic cell-derived exosomes as cell-free peptide-based vaccines.Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.Dendritic cell maturation overrules H-2D-mediated natural killer T (NKT) cell inhibition: critical role for B7 in CD1d-dependent NKT cell interferon gamma production.Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death.CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.Natural killer cells in non-hematopoietic malignanciesDendritic cell derived-exosomes: biology and clinical implementations.Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate.Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR(+) NK cell levels correlate with disease outcome.Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells.Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC.Interferon-gamma is produced by another player of innate immune responses: the interferon-producing killer dendritic cell (IKDC).Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference.Ecto-calreticulin in immunogenic chemotherapy.The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy.Dendritic cells and innate defense against tumor cells.Killer dendritic cells and their potential role in immunotherapy.Exosomes for the treatment of human malignancies.Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease.Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancerNatural killer cell-directed therapies: moving from unexpected results to successful strategies.Killer dendritic cells: IKDC and the others.The Janus face of dendritic cells in cancer.Imatinib mesylate (Gleevec): targeted therapy against cancer with immune properties.Dendritic cell-derived exosomes for cancer immunotherapy: what's next?Exosomes: immune properties and potential clinical implementations.Dendritic cell-derived exosomes as immunotherapies in the fight against cancer.
P50
Q24801506-2FBF852D-33B1-40E5-BAA1-BE74B37311D1Q28271233-BD3484A2-84B8-46EB-9896-04A73119AE81Q33421740-97CAE5E8-6797-4899-B02F-D80EB5105FD2Q34187201-E2495290-E7E4-42E1-BDC0-3FBD18FCC53BQ34545292-D9492A5D-3F27-4BAC-8065-4A6F1484BBB0Q34681370-5455D781-22DC-4BE9-A616-9BF8EDE81973Q34836082-D48CB505-39C1-4334-9AD3-10210026872BQ35109585-D2E26475-EF55-4AE2-B9F7-102E48A4D19EQ35195998-09606CD0-E2E2-45EA-BFF3-DAB966417417Q35630835-930B60F5-190B-4E91-8B02-C36EA5799AE4Q35833921-097F415C-A895-4F0C-A29C-7B1F6F6DC429Q36161201-861B6AAB-2E1C-4E9F-84C2-BAD3CF9845D6Q36199323-2D94E05E-9094-4700-A666-FF682CE9F855Q36209651-608AD3E2-5F04-4F8E-BF01-6C971A6C25B6Q36293343-AEFB6CE5-32DA-44C9-90A2-99796860390CQ36369610-8144A1F6-306F-4F07-A3A3-ED7E2D6229FBQ36403093-833BAFE1-218B-4706-BE34-6A3BAEDFDD75Q36403637-93335B6E-7285-41E6-8226-CD9DBEF38EDBQ36486204-F4D98C67-C188-4BD8-8389-4573E098DAD8Q36523645-4A1286E6-5BDD-415F-81CE-085F6812512AQ36694926-19F48E54-3EE3-4BFB-B38D-8CBE2D0CBD0FQ36694931-054E94E1-641E-4B61-83C1-180D4D4116D4Q36729361-35D82FAE-7AC4-40A9-BC0B-5AD143109EAFQ36821101-8F894931-246E-4D32-9404-43217A73A2D0Q36851583-A404FAB2-CF0F-47A7-A326-B88716584A48Q36949870-7836A383-80BA-4C22-84A1-A35C3E5BFB36Q36990570-C35F8C31-2FA3-402B-9C16-C0CB0D737AC3Q36990578-D687531F-140A-46CE-852D-AEE81BC45C0DQ37044174-E2D26D9A-C1D2-4271-B4DC-8000CC96CB56Q37088100-AD85C40D-51A9-497F-AC46-3D9C09C6FA00Q37088104-A9E0021C-F327-4657-B861-4F65E6B61BBDQ37098427-E0F82F2B-CA6D-4E50-B60F-4FE8706B2BDFQ37111136-AF015AC2-2177-490E-9AAE-A7B33E3CE7F3Q37143139-80EC423A-6D88-488A-B76D-80117D70C4C6Q37191524-0F9CCA8D-2F10-41FD-A0CF-1D5B284D5405Q37287170-5B11EF9C-B512-481B-9280-358F03F26E83Q37617459-26BEAE03-FD70-4C48-B0E3-4D3F1A10CE9FQ37690060-28F5B8C1-53D5-4874-A213-037B5E030681Q37822692-5A233711-4C96-4D4C-9BD2-D4D9144BCDDAQ38232560-F9B1EAF5-3D38-426B-9C1A-AC7D718FA16F
P50
description
Frans immunologe
@nl
inmunóloga francesa
@ast
researcher ORCID ID = 0000-0003-2506-7853
@en
عالمة مناعة فرنسية
@ar
name
Nathalie Chaput
@ast
Nathalie Chaput
@ca
Nathalie Chaput
@en
Nathalie Chaput
@es
Nathalie Chaput
@fr
Nathalie Chaput
@nl
Nathalie Chaput
@sl
type
label
Nathalie Chaput
@ast
Nathalie Chaput
@ca
Nathalie Chaput
@en
Nathalie Chaput
@es
Nathalie Chaput
@fr
Nathalie Chaput
@nl
Nathalie Chaput
@sl
altLabel
Nathalie Chaput-Gras
@en
Nathalie Gras-Chaput
@en
prefLabel
Nathalie Chaput
@ast
Nathalie Chaput
@ca
Nathalie Chaput
@en
Nathalie Chaput
@es
Nathalie Chaput
@fr
Nathalie Chaput
@nl
Nathalie Chaput
@sl
P214
P269
P4285
P106
P2038
Nathalie_Chaput
P21
P213
0000 0001 3958 913X
P214
P269
P27
P31
P4285
P496
0000-0003-2506-7853
P569
1974-01-01T00:00:00Z
P6634
nathalie-chaput-6a893858
P734
P735
P7859
viaf-197092139